A patient-friendly guide by RealMedVision.
Medically reviewed | 10–12 min read
If you have come across the Poviztra injection recently and are not sure what it is, you are not alone. Emcure Pharmaceuticals launched it in India as a second brand of Novo Nordisk’s weight management drug, the same molecule sold worldwide as Wegovy, not a generic copy. It comes in five strengths, from 0.25 mg to 2.4 mg, and its price dropped by nearly half in April 2026 once generic competition picked up. Here is what it treats, how it works, what it costs, and who should avoid it.
Quick Answer
- Poviztra is a semaglutide injection, the same active ingredient as Wegovy, sold in India by Emcure Pharmaceuticals under a second brand name.
- It is approved for chronic weight management in adults and should always be used alongside a reduced-calorie diet and regular physical activity.
- Poviztra is available in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg.
- Following the April 2026 price revision, the monthly cost ranges from approximately ₹3,999 to ₹8,999, depending on the prescribed strength.
- Poviztra is not approved for treating type 2 diabetes in India. Semaglutide for diabetes is marketed under the brand Ozempic.
What Is Poviztra?
Semaglutide is the active ingredient here, and it belongs to a class of medicines called GLP-1 receptor agonists. The molecule was first developed for type 2 diabetes and later approved separately for long term weight management under the brand name Wegovy. Poviztra is that same weight management formulation, sold in India through an exclusive distribution deal that Emcure Pharmaceuticals signed with Novo Nordisk in November 2025, with the product hitting pharmacy shelves the following month. [semaglutide brands in India]
Not a Generic Copy
People often assume Poviztra is a budget alternative to Wegovy. It is not. It is the same medicine under a different name in the Indian market, sold and priced independently by Emcure rather than made by another manufacturer. The many generic semaglutide brands that flooded the market after Novo Nordisk’s core patent expired in March 2026 are a separate story, and they are usually priced lower still.
Why the Price Dropped So Fast
What made the timing interesting is that Emcure had to react fast. Within weeks of the patent expiry opening the door to generics, the company cut Poviztra’s price by close to half just to stay competitive, even though it still carries the original Novo Nordisk approval rather than a generic license. [Wegovy price in India]
The pen itself is simple. It is a prefilled, once weekly injection device meant for use at home, so there is no need to visit a clinic or wait for a nurse every time a dose is due.
The Evidence Behind It
Poviztra is not a new or untested molecule. It draws on data from the STEP and SELECT clinical trial programmes, the same studies behind Wegovy’s international approval, plus nearly a decade of real world semaglutide use globally. In the pivotal STEP 1 trial, participants on semaglutide 2.4 mg lost an average of 14.9 percent of body weight over 68 weeks, compared with 2.4 percent on placebo, and a meaningful share of participants reached 20 percent or more. SELECT, a separate trial, studied cardiovascular outcomes in people with obesity and existing heart disease. Results varied between participants, and not everyone achieved the same degree of weight loss.
Poviztra Dosage Strengths and Price in India
Five strengths make up the Poviztra lineup. The lower ones are there to ease the body into treatment during the first few weeks, and the higher ones are used once the body has adjusted, for ongoing weight management. Below is how pricing looked at launch in December 2025, compared with the revised pricing that came into effect from April 2026. [Ozempic price in India article]
| Strength | Typical Role | Launch Price (December 2025) | Revised Price (from April 2026) |
|---|---|---|---|
| 0.25 mg | Starting dose | Rs 8,790 per month | Rs 3,999 per month |
| 0.5 mg | Early dose increase | Rs 11,200 per month | Rs 4,999 per month |
| 1.0 mg | Mid range dose increase | Higher than 0.5 mg tier | Not officially disclosed by Emcure. Public reporting confirmed only the 0.25 mg, 0.5 mg, and 2.4 mg revised prices, so this tier likely falls between Rs 4,999 and Rs 8,999 |
| 1.7 mg | Late dose increase | Higher than 1.0 mg tier | Not officially disclosed by Emcure. Public reporting confirmed only the 0.25 mg, 0.5 mg, and 2.4 mg revised prices, so this tier likely falls between Rs 4,999 and Rs 8,999 |
| 2.4 mg | Maintenance dose | Up to Rs 15,000 per month | Up to Rs 8,999 per month |
Good to know: prices can shift slightly by pharmacy or city, so check the current rate before buying rather than relying on last month’s figure. Each monthly pack covers four weekly doses, and your doctor decides which strength you start on and how fast you move up.
How Does Poviztra Work?
Picture what happens after a big meal. Your gut releases a hormone called GLP-1 that tells your brain you are full, slows how quickly your stomach empties, and nudges your pancreas to release the right amount of insulin. Semaglutide mimics that hormone, sending the same signals more consistently and for longer. Over weeks and months, appetite drops and weight loss becomes more achievable, but only when paired with real changes to diet and activity. Poviztra does not work in isolation.
Who Is Poviztra For?
Who It Is Approved For
Poviztra is meant for adults who need medical support with long term weight management, specifically if you fall into one of these groups:
- A body mass index (BMI) of 30 kg per m2 or higher, which falls under obesity, or
- A BMI of 27 kg per m2 or higher, along with at least one weight related condition such as high blood pressure, type 2 diabetes, or high cholesterol [blood sugar chart by age]
It is also prescribed for adults who already live with heart disease and are overweight or obese, to lower the risk of heart attack and stroke. Either way, it comes alongside a reduced calorie diet and regular activity, never as a standalone fix.
A Quick Example
An illustrative example, not a real patient: consider Ravi, a 42 year old office worker with obesity and high blood pressure, who had tried diet and exercise alone for over a year with modest results. His doctor added Poviztra, starting low, and reviewed progress at each dose increase. Cases like this are common in clinics, though the exact dose and outcome depend on the individual.
Doctor’s Tip: Weight loss with Poviztra tends to be gradual, not sudden. Most doctors ask patients to track weight every few weeks rather than daily, since day to day fluctuations from water and food intake can be misleading.
How Is Poviztra Used?
The Weekly Routine
Once a week, same day every time, under the skin of the stomach, thigh, or upper arm. That is the routine with the Poviztra injection. If you have never used a weekly pen before, it can feel intimidating the first time, but most people find it far easier after the first dose or two. [Awiqli dosage article here, since it covers a similar once-weekly pen routine]
The Usual Dose Increase Schedule
Most people begin on the lowest strength and move up gradually, which is the standard approach for this type of medicine worldwide. A typical pattern looks like this, though your doctor sets the actual pace:
- 0.25 mg once weekly for the first 4 weeks
- 0.5 mg once weekly for the next 4 weeks
- 1.0 mg once weekly for the next 4 weeks
- 1.7 mg once weekly for the next 4 weeks
- 2.4 mg once weekly as the ongoing maintenance dose
None of this replaces what your doctor tells you directly. The right starting point and pace depend on your own health history, and that decision sits with the person treating you.
Side Effects of Poviztra
Common Side Effects
Nausea in the first few weeks is common with semaglutide medicines, especially right after a dose increase, and usually settles as the body adjusts.
Serious Side Effects Needing Attention
A smaller set of side effects are more serious and need prompt medical attention rather than a wait and watch approach.
| Common Side Effects (usually mild, often improve over time) | Serious Side Effects (seek medical help promptly) |
|---|---|
| Nausea | Severe, ongoing stomach pain, which may signal pancreatitis |
| Vomiting | Yellowing of the skin or eyes, or pain in the upper right stomach, which may signal gallbladder problems |
| Diarrhoea | A lump or swelling in the neck, hoarseness, or trouble swallowing, which may signal a thyroid problem |
| Constipation | Sudden vision changes or vision loss |
| Stomach discomfort or bloating | Signs of a severe allergic reaction, such as facial swelling, difficulty breathing, or a fast heartbeat |
| Tiredness | Symptoms of low blood sugar, such as shakiness, sweating, and confusion, especially if combined with diabetes medicines |
| Headache | Reduced urination or swelling in the legs, which may signal kidney problems |
When to Call Your Doctor: do not wait it out if you notice a neck lump, ongoing severe stomach pain, yellowing skin or eyes, sudden vision changes, or any swelling of the face and throat. These are not situations to manage at home, and getting checked quickly matters more than trying to see if it passes.
Warning: Who Should Not Use Poviztra
A few groups need to avoid Poviztra altogether or use it only under close supervision:
- A personal or family history of medullary thyroid cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- A previous serious allergic reaction to semaglutide or any ingredient in Poviztra
- A history of pancreatitis
- Pregnancy or plans to conceive, since semaglutide may harm an unborn baby and is usually stopped two months before trying
- Breastfeeding, since safety data is still limited
Patient Reminder: Never combine Poviztra with another semaglutide medicine or any other GLP-1 receptor agonist. If you already use insulin or other diabetes medicines, starting Poviztra needs direct medical supervision, since the combination can push blood sugar too low. Dosing for children or older adults is not covered here and should be discussed directly with your doctor.
Myth vs Fact
Myth: Poviztra is a cheap generic copy of Wegovy.
Fact: It carries Novo Nordisk’s original approval and is the same molecule, sold under a second brand name through Emcure.
Myth: The weight loss stays even after stopping the injection.
Fact: Weight regain is common after stopping semaglutide unless diet and activity changes continue long term.
Myth: You can skip diet changes if you are on Poviztra.
Fact: It is studied only as an addition to a reduced calorie diet and exercise, not a replacement for either.
Myth: Poviztra also treats type 2 diabetes since it contains semaglutide.
Fact: It is approved for weight management only. Semaglutide for diabetes is sold in India under a different brand, Ozempic.
Poviztra vs Ozempic vs Wegovy: What Is the Difference?
Although all three injections contain semaglutide, they are not meant for the same purpose, and switching between them is a decision for a doctor to make, not something to try on your own.
| Brand | Marketed By (India) | Primary Approved Use | Typical Dose Range |
|---|---|---|---|
| Poviztra | Emcure Pharmaceuticals (Novo Nordisk molecule) | Chronic weight management, cardiovascular risk reduction in obesity | 0.25 mg to 2.4 mg once weekly |
| Wegovy | Novo Nordisk | Chronic weight management, cardiovascular risk reduction in obesity | 0.25 mg to 2.4 mg once weekly |
| Ozempic | Novo Nordisk | Type 2 diabetes management | 0.5 mg to 2 mg once weekly |
Key Takeaways
- Confirm your BMI and any weight related conditions with a doctor before starting
- Expect a gradual dose increase over several months, not an immediate jump to 2.4 mg
- Watch for side effects around each dose increase, when symptoms are most likely
- Compare current pharmacy pricing before buying, since rates vary by location
- Learn the warning signs, neck lump, severe stomach pain, sudden vision change, and act quickly
- Remember this treats weight, not diabetes, despite sharing its ingredient with Ozempic
What People Usually Ask
What is Poviztra used for?
Doctors usually prescribe it when weight loss through diet and exercise alone has not worked, particularly for adults with obesity or excess weight plus a related condition like high blood pressure or type 2 diabetes. It works alongside those lifestyle changes, not instead of them.
Is Poviztra the same as Wegovy?
In terms of what is inside the pen, yes. Poviztra contains the same semaglutide molecule as Wegovy and is approved for the same purpose, sold in India as a second brand distributed exclusively by Emcure.
Who makes Poviztra in India?
Emcure Pharmaceuticals distributes it exclusively in India, through a partnership with Novo Nordisk, which owns and supplies the semaglutide molecule.
What are the dosage strengths of Poviztra?
Five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. Treatment starts at the lowest strength and climbs gradually every few weeks, based on your response.
How much does Poviztra cost in India?
Since the April 2026 price revision, expect roughly Rs 3,999 to Rs 8,999 a month depending on strength, for a pack of four weekly doses. Small variations by pharmacy and city are normal.
What are the common side effects of Poviztra?
Nausea, vomiting, diarrhoea, constipation, and stomach discomfort top the list, usually showing up around dose increases and settling within a few weeks.
Who should not use Poviztra?
Anyone with a personal or family history of medullary thyroid cancer or MEN 2, a history of pancreatitis, a known allergy to semaglutide, or who is pregnant or breastfeeding should avoid it. Combining it with other diabetes medicines needs medical supervision.
Is Poviztra approved for diabetes as well as weight loss?
Not currently. It sits in the same lane as Wegovy, weight management and cardiovascular risk reduction, not diabetes care. Semaglutide for diabetes is sold in India under Ozempic instead.
Important Disclaimer
Everything above is meant to inform, not to prescribe. Nothing here recommends a specific dose for you personally. Always follow what your doctor tells you about starting, changing, or stopping any medicine, including Poviztra, particularly if you are pregnant, breastfeeding, or managing diabetes, thyroid disease, or pancreatitis.
References
- Wilding JPH, Batterham RL, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021, the primary STEP 1 trial paper
- AJMC summary of the STEP 1 trial results at 68 weeks
- FDA prescribing information for Wegovy (semaglutide), 2025
- Business Standard, Emcure cuts Poviztra price by up to 55 percent, April 2026
- Business Today, Emcure Poviztra price revision report, April 2026
- The Indian Practitioner, Emcure launches Poviztra in India, December 2025
- Emcure Pharmaceuticals official press release, Poviztra launch
- Wegovy official prescribing information and medication guide, Novo Nordisk
Medically reviewed by
This guide was checked for medical accuracy by our review board before publishing.
Dr. Praveen Verma, MBBS, MD (Pathology), Pathologist and Clinical Laboratory Specialist.
Dr. Himanshu Morya, MBBS, Medical Educator.
About the author
Iraphan Khan, BSN, RN, D.Pharm, is the founder of RealMedVision and a Public Health Researcher who creates evidence-based health content from trusted medical sources.